(Q33816237)

29 July 2017

title

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases (English)

1 reference

29 July 2017

Jo-Anne H Young

3

0 references

Oliver A Cornely

object named as

Oliver A Cornely

series ordinal

1

0 references

Peter G. Pappas

series ordinal

2

object named as

Peter G Pappas

1 reference

29 July 2017

Philip Maddison

4

1 reference

29 July 2017

Andrew J Ullmann

series ordinal

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

10 February 2011

1 reference

Expert Opinion on Drug Safety

29 July 2017

published in

1 reference

29 July 2017

volume

10

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

171-183

1 reference

Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

21 January 2018

Invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Attributable mortality of nosocomial candidemia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Liposomal amphotericin B: clinical experience and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.557062

10.1517/14740338.2011.557062

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference